US accelerates psychedelic research amid colonial legacies and profit-driven biomedical extraction: systemic risks of ibogaine and beyond
Original framing: “US speeds research into mind-altering drugs — including mysterious 'ibogaine'” — Nature
The original framing omits the colonial extraction of iboga from Gabon and Cameroon, the erasure of Bwiti spiritual practices in Central Africa, and the lack of Free, Prior, and Informed Consent (FPIC) in research. It also ignores historical parallels like the 1950s-60s CIA’s MK-Ultra program using psychedelics for psychological warfare, or the 19th-century opium trade’s exploitation of Asian medicinal traditions. Marginalized voices—such as African healers, Amazonian ayahuasca practitioners, or Black and Indigenous communities disproportionately targeted by drug policies—are absent. The systemic risks of pharmaceutical monopolization and the environmental impact of iboga cultivation are also overlooked.
Medium structural omission detected in mainstream coverage.
The narrative is produced by Western scientific institutions (e.g., Nature, NIH) and pharmaceutical interests, serving a biomedical-industrial complex that prioritizes patentable treatments over holistic or indigenous frameworks. Framing psychedelics as 'mind-altering drugs' reinforces stigma while positioning the US as a leader in their 'safe' commercialization. This obscures the role of colonial histories in the appropriation of psychoactive plants and the power imbalances in global knowledge production, where Global South communities bear the ecological and cultural costs of extraction.
Iboga’s cultural and spiritual significance in Bwiti traditions of Gabon and Cameroon is reduced to a 'mysterious compound' in Western discourse, erasing centuries of indigenous pharmacopeia and ethical frameworks. The iboga shrub’s overharvesting for pharmaceutical research mirrors colonial extraction of quinine and rubber, where Global South ecosystems and knowledge systems were treated as infinite resources. Indigenous healers warn that ibogaine’s clinical isolation strips the plant of its holistic healing properties, which require ritual context and community support to mitigate risks like cardiac toxicity.
The US’s acceleration of psychedelic research is not merely a biomedical breakthrough but a reenactment of colonial extraction and neoliberal commodification, where ibogaine’s 'mysterious' allure obscures its roots in Gabon’s Bwiti traditions and the ecological violence of overharvesting.